scholarly journals A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients

2021 ◽  
Author(s):  
Ilies Benotmane ◽  
Timothée Bruel ◽  
Delphine Planas ◽  
Samira Fafi-Kremer ◽  
Olivier Schwartz ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Neutralizing Antibody ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Serum Neutralization ◽  
Before And After ◽  
Fourth Dose ◽  
Alpha Variant ◽  
Kinetics Of

In immunocompetent subjects, the effectiveness of SARS-CoV-2 vaccines against the delta variant appears three-to five-fold lower than that observed against the alpha variant. Additionally, three doses of SARS-CoV-2 mRNA-based vaccines might be unable to elicit a sufficient immune response against any variant in immunocompromised kidney transplant recipients. This study describes the kinetics of the neutralizing antibody (NAbs) response against the delta strain before and after a fourth dose of a mRNA vaccine in 67 kidney transplant recipients who had experienced a weak antibody response after three doses. While only 16% of patients harbored NAbs against the delta strain prior to the fourth injection – this percentage raised to 66% afterwards. We also found that, after the fourth dose, the NAbs titer increased significantly (p=0.0001) from <7.5 (IQR : <7.5 –15.1) to 47.1 (IQR <7.5–284.2). Collectively, our data indicate that a fourth dose of the mRNA-1273 vaccine in kidney transplant recipients with a weak antibody response after three previous doses improves serum neutralization against the delta variant.

scholarly journals Antibody response to a fourth mRNA Covid-19 vaccine boost in weak responder kidney transplant recipients

2021 ◽  
Author(s):  
Sophie Caillard ◽  
Olivier Thaunat ◽  
Ilies Benotmane ◽  
christophe masset ◽  
Gilles Blancho
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Organ Transplant ◽  
Vaccine Dose ◽  
Immunosuppressive Drugs ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Fourth Dose ◽  
Us Fda

The US FDA has recently authorized immunocompromised people to receive a third dose of mRNA Covid-19 vaccine following the two-doses regimen to further boost protection. Unfortunately, a non-negligible proportion of people treated with immunosuppressive drugs either do not respond or show only a weak response after a third boost and should, therefore, still be considered at risk of severe Covid-19. As of June 2021, we were granted the opportunity to offer a fourth vaccine dose to French solid organ transplant recipients who still showed a weak antibody response after the third dose. In this multicenter study, we demonstrate that that the protection conferred by a fourth dose is adequate for the majority of kidney transplant recipients

Safety and Antibody Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Kidney Transplant Recipients

2021 ◽  
Vol 05 (04) ◽  
Author(s):  
Ali AlShaqaq ◽  
Maher AlDemerdash ◽  
Abdulnaser AlAbadi ◽  
Baher Elgadaa ◽  
Najib Musaied ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis

2018 ◽  
Vol 20 (4) ◽  
pp. e12919 ◽  
Author(s):  
Geovana Basso ◽  
Claudia Rosso Felipe ◽  
Marina Pontello Cristelli ◽  
Juliana Mansur Siliano ◽  
Laila Viana ◽  
...  
Keyword(s):  
Viral Load ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Kinetics Of

scholarly journals SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study)

2021 ◽  
Author(s):  
Jackrapong Bruminhent ◽  
Chavachol Sethaudom ◽  
Pongsathon Chaumdee ◽  
Sarinya Boongird ◽  
Sasisopin Kiertiburanakul ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Organ Transplant ◽  
Calcineurin Inhibitors ◽  
Neutralizing Antibody ◽  
Cell Mediated Immunity ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cell Responses ◽  
Clinical Trials Registry

Immunogenicity following inactivated SARS-CoV-2 vaccination among solid organ transplant recipients has not been assessed. Seventy-five patients (37 kidney transplant [KT] recipients and 38 non-transplant controls) received two doses, at 4-week intervals, of an inactivated whole-virus SARS-CoV-2 vaccine. SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity (CMI) were measured before, 4 weeks post-first dose, and 2 weeks post-second dose. The median age of KT recipients was 50 years (IQR, 42 to 54) and 89% were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median time since transplant was 4.5 years (IQR, 2 to 9.5). Among 35 KT patients, anti-RBD IgG titer after vaccination was not significantly different to baseline, but was significantly lower than in controls (7.8 [95%CI 0.2 to 15.5] vs 2,691 [95%CI 1,581 to 3,802], p<0.001) as well as the percentage of surrogate virus neutralizing antibody inhibition (2 [95% CI -1 to 6] vs 71 [95%CI 61 to 81], p<0.001). However, the mean of SARS-CoV-2 mixed peptides-specific T-cell responses measured by enzyme-linked immunospot assays was significantly increased compared with baseline (66 [95%CI 36 to 99] vs. 34 [95%CI 19 to 50] T-cells/10^6 PBMCs, p=0.02) and comparable to that in controls. Our findings revealed weak HMI and marginal CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccine. (Thai Clinical Trials Registry, TCTR20210226002).

scholarly journals Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients

2021 ◽  
Author(s):  
Roman Reindl-Schwaighofer ◽  
Andreas Heinzel ◽  
Manuel Mayrdorfer ◽  
Rhea Jabbour ◽  
Thomas M. Hofbauer ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Vaccine Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients

Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0003512021
Author(s):  
Thilo Kolb ◽  
Svenja Fischer ◽  
Lisa Müller ◽  
Nadine Lübke ◽  
Jonas Hillebrandt ◽  
...  
Keyword(s):  
Immune Responses ◽  
Kidney Transplant ◽  
Kidney Failure ◽  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Dialysis Patients ◽  
Specific Antibodies ◽  
Neutralization Capacity

Background: Kidney failure patients on dialysis or after renal transplantation have a high risk for severe COVID-19 infection and vaccination against SARS-CoV-2 is the only expedient prophylaxis. Generally, immune responses are attenuated in kidney failure patients, however, systematic analyses of immune responses to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients (KTR) are still missing. Methods: In this prospective multicentric cohort study, antibody responses COVID-19 mRNA vaccines (BNT162b2; Biontech/Pfizer or mRNA-1273; Moderna) were measured in 32 dialysis patients and in 28 KTRs. SARS-CoV-2-specific antibodies and neutralization capacity were evaluated and compared to controls (n=78) in a similar age-range. Results: After the first vaccination, SARS-CoV-2-specific antibodies were nearly undetectable in kidney failure patients. After the second vaccination, 93% of the controls and 88% of dialysis patients but only 37% of KTRs developed SARS-CoV-2-specific IgG above cut-off. Moreover, mean IgG levels were significantly lower in KTRs (54±93 BAU/ml) compared to dialysis patients (503±481 BAU/ml, p<0.01). Both KTRs as well as dialysis patients had significantly lower IgG levels compared to controls (1992±2485 BAU/ml; p<0.001 and p<0.01). Importantly, compared to controls, neutralizing antibody titers were significantly lower in KTRs and dialysis patients. After the second vaccination, 76% of KTRs did not show any neutralization capacity against SARS-CoV-2 suggesting impaired seroprotection. Conclusions: Kidney failure patients show a significantly weaker antibody response compared to controls. Most strikingly, only one out four KTRs developed neutralizing antibodies against SARS-CoV-2 after two doses of vaccine. These data suggest that vaccination strategies need modification in immune transplant and dialysis patients.

Kinetics of T-Lymphocyte Subsets and Posttransplant Opportunistic Infections in Heart and Kidney Transplant Recipients

2012 ◽  
Vol 93 (1) ◽  
pp. 112-119 ◽  
Author(s):  
Sandra A. Calarota ◽  
Paola Zelini ◽  
Annalisa De Silvestri ◽  
Antonella Chiesa ◽  
Giuditta Comolli ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
T Lymphocyte ◽  
Lymphocyte Subsets ◽  
Opportunistic Infections ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
T Lymphocyte Subsets ◽  
Kinetics Of
Sign in / Sign up

Export Citation Format

Share Document